MoU signed to establish cell, stem-cell quality control centre in Vietnam
A Memorandum of Understanding (MOU) has been signed between Hoa Lam Shangri-La Healthcare of Hoa Lam Group and Japan-based Cyto-Facto Inc to collaborate in establishing a quality control centre for cells and stem cells in Vietnam that meets international standards.
Hoa Lam Shangri-La Healthcare signs an MoU with Japan-based Cyto-Facto Inc to partner in developing cell therapy, stem cells, and gene therapy. (Photo courtesy of Hoa Lam Group)
HCM City (VNS/VNA)🗹 - A Memorandum of Understanding (MOU) has been signed between Hoa Lam Shangri-La Healthcare of Hoa Lam Group and Japan-based Cyto-Facto Inc to collaborate in establishing a quality control centre for cells and stem cells in Vietnam that meets international standards.
Under the MOU, the two sides will partner to develop cell therapy, stem cells, and gene therapy.
Cyto-Facto Inc will provide training, consultation, and technology transfer in cell and stem cell production (including mesenchymal stem-cell production from knee synovial membrane) according to Japanese quality control standards.
It will provide consultative support in implementing automated cell and stem cell processing systems for Hoa Lam Shangri-La Healthcare.
It will also consult and help Hoa Lam Shangri-La Healthcare to establish a quality control centre for cells and stem cells, adhering to international quality standards.
Tran Thi Lam, founder and chairwoman of Hoa Lam Group, said this partnership is expected to promote the development of the group’s Hoa Lam Shangri-La High-Tech Medical Zone in Bình Tan district providing international standard medical services for people in Vietnam and other countries in Southeast Asia, especially in the fields of stem cells and regenerative medicine.
Stem cells are widely utilised in regenerative medicine and chronic disease treatment.
Vietnam’s healthcare sector has successfully implemented hematopoietic stem-cell transplants (bone marrow transplant) in treating blood cancer, used adipose-derived stem cells for knee osteoarthritis treatment, and applied stem cells for cardiovascular disease treatment and chronic obstructive pulmonary disease.
International collaboration in stem-cell research, development, and application, particularly with Japan renowned as the “cradle” of cellular technology with three Nobel Prizes in Biomedicine, will provide enhanced healthcare opportunities for millions of Vietnamese patients suffering from chronic and severe illnesses.
Cyto-Facto Inc, located in Kobe City of Japan, which is the first company separated from the Foundation for Biomedical Research and Innovation at Kobe (FBRI), is a core organisation within the Kobe Biomedical Innovation Cluster (KBIC), Japan's largest life sciences and biomedical cluster.
It has accumulated extensive manufacturing technology experience and has implemented production lines for stem cells and immune cells, including CAR-T cells (Chimeric Antigen Receptor T-cells), iPS cells (induced Pluripotent Stem cells), and MSC (Mesenchymal Stem Cells) at various developmental stages.
It is recognised as Asia’s first company to manufacture commercial CAR-T products under the Good Manufacturing Practices (GMP) standards of Pharmaceutical Inspection Cooperation Scheme (PIC/S)./.
The Hanoi-based Hoang Lam Cosmetic Pharmaceutical Joint Stock Company has signed a memorandum of understanding (MoU) with India’s Stempeutics Research Pvt. Ltd. to introduce stem cell technology in Vietnam.
Singapore has asked Cordlife, one of Asia's largest stem cell bank providers, to tighten supervision of its processes after improper handling ruined thousands of samples, an official has said.
Vietnam now boasts a nationwide healthcare network with 1,665 hospitals, 384 of which are non-public, supported by local commune- and ward-level stations. At the end of 2024, hospital bed capacity reached 34 per 10,000 people, slightly above the global average.
The 56-year-old patient from Quang Tri province was discharged in stable condition as he no longer experienced shortness of breath and was able to walk, move around, and eat normally.
Associate Professor Dr. Nguyen Vu Trung, Director of the Pasteur Institute, said that under the MoU, the two sides committed to promoting diverse and practical collaborative activities, including joint conferences and workshops, exchanges of scholars, researchers and students, sharing academic materials, and the development of specific programmes and projects in scientific research, training, and epidemic prevention.
TytoCare, a leading Israeli telemedicine company based in Netanya, is willing to work with Vietnamese regulators, insurers, and healthcare providers to develop a sustainable digital health ecosystem.
The partnership is under the framework of a Memorandum of Understanding on the development and implementation of the National Action Plan on Breast Cancer and Cervical Cancer Prevention and Control, signed in Hanoi on July 22.
An estimated 7 million Vietnamese are currently living with diabetes, but about 50% remain undiagnosed, a dangerous gap that is fuelling serious, preventable complications and increasing the burden on the healthcare system.
In 2024, Vietnam achieved 99% coverage for the first dose of the diphtheria, tetanus and pertussis vaccine, up from 80% in 2023. Immunisation coverage in the country has not only rebounded to the high levels seen before the COVID-19 pandemic but has now surpassed the rates recorded in 2019.
Health authorities in HCM City have issued an urgent alert after six people died from dengue fever, amid a spike in infections driven by the onset of the rainy season.
During the peak months of July and August 2025, the National Institute of Haematology and Blood Transfusion (NIHBT) needs at least 90,000 units of blood to supply 180 hospitals in the northern region. However, despite continuous efforts, the reserve blood is still short of 30,000 units.
The Hanoi ceremony highlighted efforts to ensure all citizens, especially women and youth, can access accurate information and healthcare services to make informed reproductive choices.
After such a long time, the law has revealed many limitations, prompting the Ministry of Health (MoH) to gather opinions to amend the law to give more chances to thousands of patients every year.
Currently, cardiovascular specialists from the 108 Military Central Hospital are working alongside a team of Prof.Dr. Jan D. Schmitto, Deputy Director of MHH’s Department of Cardiac, Thoracic, Transplantation and Vascular Surgery on clinical trials for MCS devices, implanted in heart failure patients either as a bridge to transplantation or as permanent treatment.
The centre not only serves residents living on the island, but also receives tens of thousands of visitors every year, according to Assoc Prof Dr Tang Chi Thuong, Director of the HCM CIty Department of Health.
Not only does Vietnam attract international tourists with its landscapes, culture, and cuisine, but it is also gradually becoming a reliable destination for medical treatment, offering high-quality services at reasonable costs.
Over the past six months, 150 communal health stations in provinces including Ha Giang, Bac Kan, Lang Son, Lao Cai, Lai Chau, Yen Bai, Tay Ninh, Hau Giang, Ben Tre and Ca Mau have been equipped with information technology systems. In addition, 117 key provincial healthcare workers have received training, with thousands more expected to follow.
During the COVID-19 pandemic in 2020, the Ministry of Health swiftly launched a telemedicine programme, connecting more than 1,000 medical establishments nationwide. The model, which remains in operation, has benefited tens of thousands of patients, including foreign nationals.
After more than three weeks of intensive treatment, the patient's pneumonia improved, breathing stabilised, sedation was reduced, and the breathing tube was removed. He is now conscious, able to eat orally, and in recovery.
